Meralgia paresthetica successfully treated with palmithoylethanolamide

Rocco Salvatore Calabrò, Carmela Casella, Alfredo Manuli, David Militi, Giuseppe Gervasi

Research output: Contribution to journalArticle


Meralgia paresthetica (MP) is an uncommon entrapment mononeuropathy that is characterized by a sudden onset of paresthesia and numbness in the anterolateral surface of the thigh. Palmithoylethanolamide (PEA) is commonly used in the treatment of chronic pelvic pain and compressive neuropathies. Herein, we describe an otherwise healthy 28-year-old patient affected by posttraumatic MP for three months who was successfully treated with PEA (1200mg/day). Further studies are needed to better investigate the potential use of PEA as therapeutic drug in peripheral neuropathies, including MP, to avoid or delay more invasive surgical treatments.

Original languageEnglish
Pages (from-to)10-11
Number of pages2
JournalInnovations in Clinical Neuroscience
Issue number7-9
Publication statusPublished - Jul 1 2020


  • Inflammation
  • Nutraceuticals
  • Polyneuropathy

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Meralgia paresthetica successfully treated with palmithoylethanolamide'. Together they form a unique fingerprint.

Cite this